EP2293790A2 - Kombination aus einem partiellen nikotinrezeptoragonist und einem acetylcholinesterasehemmer, pharmazeutische zusammensetzung damit und ihre verwendung bei der behandlung kognitiver störungen - Google Patents

Kombination aus einem partiellen nikotinrezeptoragonist und einem acetylcholinesterasehemmer, pharmazeutische zusammensetzung damit und ihre verwendung bei der behandlung kognitiver störungen

Info

Publication number
EP2293790A2
EP2293790A2 EP09769521A EP09769521A EP2293790A2 EP 2293790 A2 EP2293790 A2 EP 2293790A2 EP 09769521 A EP09769521 A EP 09769521A EP 09769521 A EP09769521 A EP 09769521A EP 2293790 A2 EP2293790 A2 EP 2293790A2
Authority
EP
European Patent Office
Prior art keywords
partial agonist
alpha
acetylcholinesterase inhibitor
type
nicotinic receptors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP09769521A
Other languages
English (en)
French (fr)
Inventor
Olivier Bergis
Philippe Pichat
Alexandre Urani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Publication of EP2293790A2 publication Critical patent/EP2293790A2/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the invention relates to the combination of a partial agonist of alpha 7 nicotinic receptors and an acetylcholirvestera.se inhibitor, to a pharmaceutical composition comprising the combination of the invention and its use in the treatment of cognitive disorders, and more particularly cognitive disorders related to Alzheimer 's disease.
  • the aim of the invention is to answer this technical problem by proposing a combination of a partial agonist of nicotinic receptors of alpha 7 type and of an acetylcholinesterase inhibitor.
  • Partial nicotinic alpha7-type agonists have been described as possessing pro-cognitive properties in several animal models that interrogate different types of memory or cognitive functions (Biton et al., Neuropsychopharmacology, 2007, 32. 1-16, Pichat et al., Neuropsychopharmacology, 2007, 32: 17-34).
  • a first subject of the invention relates to a combination of a partial agonist of nicotinic type alpha 7 receptors and an acetylcholinesterase inhibitor.
  • a second subject of the invention relates to a pharmaceutical composition comprising, as active ingredient, such an association.
  • a third subject of the invention relates to the use of such an association for the treatment of cognitive disorders of various origins, and more particularly cognitive disorders related to Alzheimer's disease.
  • partial agonists of the nicotinic receptors of alpha 7 type of the invention mention may be made of the agonists partial nicotinic receptors alpha 7 type of general formula (I)
  • n represents the number 0, 1 or 2
  • R 1 , R 2 , R 3 , R 4 and R 5 each represent, independently of one another, a hydrogen or halogen atom or a trifluoromethyl, trifluoromethoxy, cyano, hydroxy group,
  • R 2 and R 3 together form a group of formula -OCH 2 O- or -CH 2 CH 2 CH 2 CH 2 -, in the form of a base or of a salt of addition to an acid, hydrate or solvate.
  • t and z can take the values from 1 to 6: a carbon chain may have from t to 2 carbon atoms, for example C 1 -C 3 a carbon chain which may have from 1 to 3 atoms of carbon ;
  • halogen atom a fluorine, chlorine, bromine or iodine atom
  • alkyl group a saturated linear or branched aliphatic group.
  • an alkoxy group an -O-alkyl radical whose group alkyl is as previously defined.
  • salts of the compounds of general formula (I) that can be used according to the invention can be prepared with pharmaceutically acceptable acids, but the salts of other acids that are useful, for example, for the purification or the isolation of the compounds of formula (I) , are also part of the invention.
  • the compounds of general formula (I) may comprise one or more asymmetric carbon atoms. They can therefore exist in the form of enantiomers or diastereoisomers. These enantiomers, diastereoisomers, as well as their mixtures, including racemic mixtures, form part of the invention.
  • a first group of compounds of formula (I) that can be used according to the invention is that in which X represents an oxygen atom.
  • a second group of compounds of formula (I) that can be used according to the invention is that in which n represents the number 0.
  • a third group of compounds of formula (I) that can be used according to the invention is that in which R 1 , R 2 , R 3 , R 4 and R 5 each represent, independently of one another, a hydrogen atom. or halogen.
  • the fourth group of compounds of formula (I) that can be used according to the invention is that in which R 1 , R 2 , R 4 and R 5 each represent a hydrogen atom and R 3 represents a halogen atom.
  • a fifth group of compounds of formula (I) that can be used according to the invention is that in which X represents an oxygen atom; n represents the number 0; R 1 , R 2 , R 4 and R 5 each represent a hydrogen atom and R 3 represents a halogen atom.
  • An example of a salt of 4-bromophenyl 1,4-diazabicyclo [3.2.2] nonane-4-carboxylate which can be used according to the invention is the fumarate salt ((2E) -but-2-enedioate).
  • the acetylcholinesterase inhibitor may be chosen from all the acetylcholinesterase inhibitors known in the literature.
  • combination according to the invention is the combination consisting of (2E) -but-2-enedioate 4-bromophenyl 1,4-diazabicyclo [3.2.2] nonane-4-carboxyléite and donepezil.
  • the pharmaceutical composition contains a minimum active dose of each active ingredient present in the combination according to the invention.
  • the invention also relates to a pharmaceutical composition containing a sub-active dose of each active ingredient present in the combination according to the invention.
  • a pharmaceutical composition containing a sub-active dose of each active ingredient present in the combination according to the invention.
  • the use of such sub-active doses may make it possible to avoid the side effects of one or more active ingredients present in the combination according to the invention.
  • the excipients are selected according to the desired pharmaceutical form and method of administration from among the usual excipients which are known to those skilled in the art.
  • the composition may be administered orally, parenterally or rectally.
  • Suitable unit dosage forms include oral forms such as tablets, soft or hard capsules, powders, granules and oral solutions or suspensions, sublingual, oral, intracheal, intraocular, intranasal forms of administration by inhalation, topical, transdermal, subcutaneous, intra-muscular or intravenous administration forms, rectal administration forms and implants.
  • the active ingredients according to the invention can be used in creams, gels, ointments or lotions.
  • the two active ingredients are administered in the same way, for example the oral route, or one of the active ingredients is administered according to a first route, for example the oral route, and the other active ingredient is administered in a different way, for example the parenteral route.
  • the active ingredients are mixed with one or more pharmaceutical excipients, such as gelatin, starch, lactose, magnesium stearate, talc, silica, gum arabic, mannitol, microcrystalline cellulose, hypromellose or the like.
  • pharmaceutical excipients such as gelatin, starch, lactose, magnesium stearate, talc, silica, gum arabic, mannitol, microcrystalline cellulose, hypromellose or the like.
  • the doses depend on the desired effect, the duration of treatment and the route of administration used.
  • the daily doses of each of the active ingredients of the combination according to the invention are as follows: partial agonists of nicotinic receptors of alpha 7 type: between 0.5 and 500 mg per day and per person, in particular between 1 and 100 mg per day and per person; acetylcholinesterase inhibitor: between 3 and 200 mg per day and per person, in particular between 5 and 100 mg per day and per person,
  • a unitary form of administration of the alpha 7-type nicotinic receptor-type partial agonist in the form of a tablet comprises the following ingredients:
  • a unitary form of administration of the acetylcholinesterase inhibitor in the form of a tablet may comprise 10 mg of the acetylcholinesterase inhibitor and of the usual excipients, for example microcrystalline cellulose, silica colloidal, talc, croscarmellose sodium, magnesium stearate.
  • the two active ingredients can be combined in a single pharmaceutical composition, comprising the two active ingredients, such as a tablet or a capsule.
  • the two active ingredients may also, whether administered simultaneously or not, be present in separate pharmaceutical compositions.
  • the combination according to the invention may be in the form of a kit comprising, on the one hand, at least one partial agonist of nicotinic receptors of alpha 7 type as defined above and, on the other hand at least one acetylcholinesterase inhibitor as hereinbefore defined, the alpha 7 nicotinic receptor partial agonist and the acetylcholinesterase inhibitor being in separate compartments and intended to be administered simultaneously, separately or spread over time (sequential administration).
  • Another subject of the invention relates to the use of an association as described above for the preparation of a medicinal product intended for the treatment of cognitive disorders, and more particularly cognitive disorders related to Alzheimer 's disease.
  • the invention also relates to a method for treating cognitive disorders, and more particularly cognitive disorders related to Alzheimer's disease, which comprises administering to a patient a minimum active or sub-active dose of a alpha-type nicotinic receptor partial agonist as defined above, and a minimum active or sub-active dose of an acetylcholinesterase inhibitor as defined above, said doses being administered simultaneously, separately or separately. sequential, as described above.
  • the aim is to highlight the superior effect of the association on the amplitude of the pro-cognitive pharmacological effect compared to the effect produced by the two active ingredients taken individually in the treatment of these cognitive disorders.
  • a first study aimed at demonstrating in the adult rat a procognitive synergy of the combination according to the invention in an episodic visual memory task, using a spontaneous forgetfulness protocol in the object recognition test.
  • Phase of habituation Given this protocol, the animals are first subjected to a session of habituation to the environmental context (a wooden enclosure of 65 x 45 x 45 cm) for a duration of 2 minutes. The time spent in active locomotion is measured using a stopwatch.
  • Reminder session The reminder session takes place after 24h for all groups.
  • the rats are confronted with a pair of objects consisting of the object encountered during the learning phase, and an unknown object.
  • the rats are deposited in the same way as for the learning session.
  • the exploration of an object is counted if the animal orients its muzzle towards the object, within a perimeter of 2 centimeters around it, or he touches him with his muzzle or paws. If the rat turns around the object or sits above, these behaviors are not considered exploratory.
  • test compounds are administered orally 60 minutes (rat study) before each of the three sessions of the protocol.
  • the exploration times of the two objects expressed in seconds and the recognition index (exploration duration of the new object / total exploration time new and familiar objects) are measured.
  • Similar exploration times vis-à-vis the familiar object and the new object reflect an oblivion of the familiar object and therefore a deficiency of episodic visual memory.
  • a longer duration of exploration of the new object than of the familiar object reflects a significant rernemoration of the familiar object and thus an improvement of the episodic visual memory.
  • a low recognition index indicates an oblivion of the familiar object and therefore a deficiency of the episodic visual memory.
  • Figure 1 and Table 1 show the time spent in locomotion during the session of accommodation for each of the experimental groups.
  • Table 2 and Figures 2 and 3 show: the duration of exploration (in seconds) of the two objects, new and familiar; and the recognition index as defined above; during the booster session for each of the experimental groups.
  • amyloid peptide A ⁇ 25-35 is dissolved in distilled water at a final concentration of 3 mg / ml. It is then incubated at 37 ° C for A days to form aggregates of toxic peptide.
  • the control animals receive the mixed peptide ("scrambled peptide"), consisting of the same amino acids, but organized in a random sequence. This mixed peptide has no neuronal (non-toxic) toxicity.
  • the behavioral experimental protocol used is comparable to that used in the test of spontaneous forgetfulness in rats, described above.
  • mice Phase getting used; In this protocol, the mice are first subjected to a session of habituation to the environmental context ⁇ a light gray PVC enclosure of 52 x 52 x 40 cm, lighting at 6 Lux) for a duration of 10 minutes. The time spent in active locomotion is measured using a stopwatch.
  • Reminder session The reminder session takes place after a 1-hour forget-out period for all groups. This short period of forgetfulness induces good booster performance in control animals and makes it possible to demonstrate a deficit induced by the injection of toxic peptide in the other animals.
  • the mice are confronted with a pair of objects consisting of the object encountered during the learning phase, and an unknown object. The mice are deposited in the anceinte in the same way as for the learning session. This test lasts 5 minutes during which we measure the time spent exploring each of the 2 objects.
  • An animai control will present, for this period of short forgetfulness, a more important exploration of the new object, translating a significant remembrance of the familiar object.
  • deficit animals will have exploration durations of the two objects that are not statistically different.
  • the exploration of an object is counted if the animal orients its muzzle towards the object, within a perimeter of 2 centimeters around it, or 'he touches him with his snout or his paws' If the rat turns around the object or sits on it, these behaviors are not considered exploratory.
  • the raw data is expressed in seconds.
  • the compounds to be tested are administered intraperitoneally, 60 minutes before each of the three sessions of the protocol.
  • the index of recognition (duration of exploration of the new object / total duration of exploration of new and familiar objects) is also measured.
  • a low recognition index reflects an omission of the familiar object and therefore a complete abolition of short-term recall performance.
  • the set of results obtained in the two series of experiments above demonstrates the superior effect of the combination according to the invention in terms of efficacy with respect to each of the active ingredients administered in isolation and at the same dosage. on visual episodic memory disorders in a task of object recognition in rodents. This superior effect is observed not only in non-deficient animals whose performance is improved, but also in a pathophysiological model of Alzheimer's disease, using intracerebral injections of toxic amyloid peptide.
  • This higher effect is representative of the effectiveness of the combination according to the invention on cognitive disorders, and more particularly on the cognitive disorders related to Alzheimer's disease, a pathology for which this type of cognitive function is known to be particularly impaired.

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP09769521A 2008-06-02 2009-06-02 Kombination aus einem partiellen nikotinrezeptoragonist und einem acetylcholinesterasehemmer, pharmazeutische zusammensetzung damit und ihre verwendung bei der behandlung kognitiver störungen Withdrawn EP2293790A2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0802996A FR2931677B1 (fr) 2008-06-02 2008-06-02 Association d'un agoniste partiel des recepteurs nicotiniques et d'un inhibiteur d'acetylcholinesterase, composition la contenant et son utilisation dans le traitement des troubles cognitifs
PCT/FR2009/051041 WO2009156680A2 (fr) 2008-06-02 2009-06-02 Association d'un agoniste partiel des recepteurs nicotiniques et d'un inhibiteur d'acetylcholinesterase, composition pharmaceutique la contenant et son utilisation dans le traitement des troubles cognitifs

Publications (1)

Publication Number Publication Date
EP2293790A2 true EP2293790A2 (de) 2011-03-16

Family

ID=40229706

Family Applications (1)

Application Number Title Priority Date Filing Date
EP09769521A Withdrawn EP2293790A2 (de) 2008-06-02 2009-06-02 Kombination aus einem partiellen nikotinrezeptoragonist und einem acetylcholinesterasehemmer, pharmazeutische zusammensetzung damit und ihre verwendung bei der behandlung kognitiver störungen

Country Status (14)

Country Link
US (1) US20110136791A1 (de)
EP (1) EP2293790A2 (de)
JP (1) JP2011522017A (de)
KR (1) KR20110021946A (de)
CN (1) CN102046164B (de)
AU (1) AU2009264016B2 (de)
BR (1) BRPI0913236A2 (de)
CA (1) CA2726291A1 (de)
FR (1) FR2931677B1 (de)
IL (1) IL209601A0 (de)
MX (1) MX2010013241A (de)
RU (1) RU2493851C2 (de)
SG (1) SG191623A1 (de)
WO (1) WO2009156680A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0424564D0 (en) * 2004-11-05 2004-12-08 Novartis Ag Organic compounds
US8314119B2 (en) * 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
CN103180321A (zh) 2010-09-23 2013-06-26 Abbvie公司 氮杂金刚烷衍生物的一水合物
US9829326B2 (en) 2012-04-14 2017-11-28 Audi Ag Method, system and vehicle for conducting group travel
CN103333163A (zh) * 2013-07-09 2013-10-02 广州中医药大学 一种苯并呋喃类衍生物及其制备方法和应用
PL3200828T3 (pl) * 2014-10-03 2021-01-25 Lachesis Biosciences Limited Kompozycje donosowe do leczenia chorób i zaburzeń neurologicznych i neurodegeneracyjnych
RU2624978C2 (ru) * 2015-07-27 2017-07-11 Государственное бюджетное образовательное учреждение высшего профессионального образования "Воронежский государственный медицинский университет им. Н.Н. Бурденко" Министерства здравоохранения Российской Федерации Способ лечения умеренного когнитивного снижения

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008028903A2 (en) * 2006-09-04 2008-03-13 Neurosearch A/S Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1121104B1 (de) * 1998-10-01 2005-01-12 Novartis AG Neue oral anzuwendende arzneizubereitungen für rivastigmine mit kontrollierter wirkstoffabgabe
FR2791678B1 (fr) * 1999-03-30 2001-05-04 Synthelabo Derives de 1,4-diazabicyclo [3.2.2] nonane-4-carboxylates et -carboxamides, leur preparation et leur application en therapeutique
US20010036949A1 (en) * 2000-05-09 2001-11-01 Coe Jotham Wadsworth Pharmaceutical composition and method of treatment of diseases of cognitive dysfunction in a mammal
ES2275808T3 (es) * 2001-02-06 2007-06-16 Pfizer Products Inc. Composiciones farmaceuticas para el tratamiento de trastornos del snc y otros trastornos.
EP1381384B1 (de) * 2001-04-24 2011-05-25 Merck Patent GmbH KOMBINATIONSTHERAPIE MIT ANTIANGIOGENEN MITTELN UND TNFalpha
CN100339070C (zh) * 2002-10-24 2007-09-26 莫茨药物股份两合公司 包含1－氨基环己烷衍生物类和乙酰胆碱酯酶抑制剂类的药物组合物
MXPA05005666A (es) * 2002-12-11 2005-07-26 Pharmacia & Upjohn Co Llc Tratamiento de enfermedades con combinaciones de agonistas del receptor nicotinico de acetilcolina alfa-7 y otros compuestos.
DE602004016850D1 (de) * 2003-06-27 2008-11-13 Pfizer Prod Inc Pyrazoloä3,4-büpyridin-6-one als gsk-3 inhibitoren
US20050043407A1 (en) * 2003-08-22 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
AU2005208871B2 (en) * 2004-01-26 2010-04-01 Cortex Pharmaceuticals Inc. Enhancement of ampakine-induced facilitation of synaptic responses by cholinesterase inhibitors
TW200533371A (en) * 2004-04-15 2005-10-16 Dainippon Pharmaceutical Co Medicament comprising a combination of an acetylcholinesterase inhibitor and a 5-substituted-3-oxadiazolyl-1,6-naphthyridin-2(1h)-one derivative
DE602005027452D1 (de) * 2004-05-07 2011-05-26 Memory Pharm Corp 1h-indazole, benzothiazole, 1,2-benzisoxazole, 1,2-benzisothiazole und chromone und deren herstellung und verwendungen
US20060194723A1 (en) * 2005-02-28 2006-08-31 Rabinoff Michael D Novel medication treatment and delivery strategies for Alzheimer's Disease, other disorders with memory impairment, and possible treatment strategies for memory improvement
EP1987033B1 (de) * 2006-02-14 2010-08-25 NeuroSearch A/S Diazabicycloalkan-derivate und ihre medizinische verwendung
EP2322168A1 (de) * 2007-04-02 2011-05-18 Parkinson's Institute Verfahren und Zusammensetzung zur Verringerung der Nebenwirkungen von therapeutischen Behandlungen
CA2714662C (en) * 2008-03-19 2016-05-10 Janssen Pharmaceutica Nv Trisubstituted 1,2,4-triazoles as nicotinic acetylcholine receptor modulators
CL2009001125A1 (es) * 2008-05-09 2011-02-11 Janssen Pharmaceutica Nv Compuestos derivados de pirazol trisustituido, moduladores alostericos positivos de los receptores ach nicotinicos; composicion farmaceutica que los comprende; proceso de preparacion de la composicion; y su uso en el tratamiento de enfermedades de snc o inflamatorias.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008028903A2 (en) * 2006-09-04 2008-03-13 Neurosearch A/S Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer

Also Published As

Publication number Publication date
HK1155943A1 (en) 2012-06-01
CN102046164A (zh) 2011-05-04
WO2009156680A3 (fr) 2010-04-22
IL209601A0 (en) 2011-02-28
SG191623A1 (en) 2013-07-31
AU2009264016A1 (en) 2009-12-30
FR2931677B1 (fr) 2010-08-20
BRPI0913236A2 (pt) 2016-01-19
CN102046164B (zh) 2013-02-20
KR20110021946A (ko) 2011-03-04
RU2010154417A (ru) 2012-07-20
FR2931677A1 (fr) 2009-12-04
US20110136791A1 (en) 2011-06-09
JP2011522017A (ja) 2011-07-28
CA2726291A1 (fr) 2009-12-30
RU2493851C2 (ru) 2013-09-27
AU2009264016B2 (en) 2014-09-11
WO2009156680A2 (fr) 2009-12-30
MX2010013241A (es) 2011-01-21

Similar Documents

Publication Publication Date Title
EP2293790A2 (de) Kombination aus einem partiellen nikotinrezeptoragonist und einem acetylcholinesterasehemmer, pharmazeutische zusammensetzung damit und ihre verwendung bei der behandlung kognitiver störungen
JP2015007096A (ja) 運動障害の予防および／または治療剤
CA2618212C (fr) Association d'un agent hypnotique a duree d'action longue et d'un agent hypnotique a duree d'action courte et son application therapeutique
WO2007041697A2 (en) Hydrogenated pyrido-indole compounds for the treatment of huntington ' s disease
FR2559061A1 (fr) Compositions analgesiques et anti-inflammatoires contenant de la diphenhydramine
JP2014525413A (ja) 糖尿病および関連障害を治療するためのモルフィナン誘導体
CN1387434A (zh) Nk1受体拮抗剂及gaba结构类似物的协同组合
CA2684172C (fr) Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo-pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des traumatismes de la moelle epiniere
CA2684174C (fr) Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo-pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des desordres moteurs lies a la maladie de parkinson
KR20110005836A (ko) 과민성 방광의 치료를 위한 유데나필과 알푸조신 또는 옥시부티닌과의 복합제의 용도
RU2544552C2 (ru) Терапевтическое средство или профилактическое средство для нейропатической боли
AU2015247921B2 (en) Sitagliptin tannate complex
WO1995007282A1 (en) Depression remedy
RU2258506C2 (ru) Лекарственные средства для предупреждения и лечения нейродегенеративных заболеваний
CA2684171C (fr) Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo-4-pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des traumatismes craniens
WO2012175894A1 (fr) Composition pharmaceutique pour le traitement de la dependance chez l'etre humain
FR3017296A1 (fr) Composition pharmaceutique pour le traitement de la dependance chez l'etre humain
HK1155943B (en) Combination of a nicotinic receptor partial agonist and of an acetylcholinesterase inhibitor, pharmaceutical composition containing same and use thereof in the treatment of cognitive disorders
BE894696A (fr) Nouveaux medicaments a base de 9,10-dihydro-ergonine pour le traitement de l'arteriosclerose

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20110103

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA RS

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SANOFI

17Q First examination report despatched

Effective date: 20110726

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SANOFI

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SANOFI

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20141216

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20150429